

**ANNETTE RID**

*October 2024*

Department of Bioethics  
The Clinical Center  
U.S. National Institutes of Health  
10 Center Drive  
Bethesda, MD 20892

annette.rid@nih.gov  
+1 301 435 8711  
bioethics.nih.gov

**CURRENT POSITION**

Bioethicist, Department of Bioethics, The Clinical Center & Department of International Science Policy, Planning and Evaluation, Fogarty International Center, U.S. National Institutes of Health (Sept 2022 - ....)

Head, Section of Global Bioethics, Department of Bioethics, The Clinical Center, U.S. National Institutes of Health (Sept 2022 - ....)

Visiting Professor, Department of Global Health & Social Medicine, King's College London (Nov 2018 - ....)

**EDUCATION**

- 2013                      Habilitation in Biomedical Ethics (~Ph.D. in Biomedical Ethics),  
University of Zurich (CH)
- 2004                      Doctor of Medicine (~MD / Ph.D. in Physiology; *summa cum laude*),  
University of Freiburg (D)
- 2003                      Medical degree (MD), University of Freiburg (D)  
With visiting studentships at St. George's Hospital Medical School  
(UK), Mount Sinai School of Medicine (US), Tulane University School  
of Medicine (US), Université Paris VI (F), Université de Toulouse (F)
- 2002                      Bachelor of Arts in Philosophy and History, University of Freiburg (D)
- 1998 / 2004              United States Medical Licensing Examination steps 1 & 2

**PAST POSITIONS**

- Sept 2018 – Feb 2023    Bioethicist, Department of Bioethics, The Clinical Center & Division of  
AIDS, National Institute of Allergy and Infectious Diseases, U.S.  
National Institutes of Health
- Sept 2018 – March  
2019                      Assistant Research Professor, Kennedy Institute of Ethics, Georgetown  
University
- Oct 2012 – Aug 2018    Senior Lecturer, then Reader (both ~Associate Professor with tenure) in

Annette Rid (née Schulz-Baldes)

Bioethics and Society, Department of Global Health & Social Medicine,  
King's College London

Oct 2011 – Sept 2012	Clinical Ethicist (part-time), University Hospital Zurich
Oct 2010 – Sept 2012	Senior Research & Teaching Fellow (~ untenured Assistant Professor), Institute of Biomedical Ethics, University of Zurich
Oct 2007 – Sept 2010	Post-doctoral Fellow, Department of Bioethics, National Institutes of Health
Oct 2005 – Sept 2007	Senior Research & Teaching Fellow (~ untenured Assistant Professor), Institute of Biomedical Ethics, University of Zurich
Sept 2005	Senior Research & Teaching Fellow (~ untenured Assistant Professor), Institute of Medical Ethics, Charité Berlin
June – Aug 2005	Scientific Coordinator, Parliamentary Commission on Ethics and Law in Medicine, German Parliament
July 2004 – June 2005	Pediatric Resident, Department of Neonatology, Charité Berlin
Jan 2004 – May 2004	Senior Ethics Fellow, Department of Ethics, Trade, Human Rights and Health Law, World Health Organization

## VISITING POSITIONS

May 2015	Visiting Scholar, ETHOX Centre, University of Oxford
June – Aug 2013	Fellow, Institute of Advanced Study, University of Konstanz
Jan – Feb 2012	Visiting Researcher, Fondation Brocher, Hermance

## RESEARCH EXPERIENCE

Conceptual bioethics	Conceptual and normative analysis
Empirical bioethics	Quantitative surveys (design, implementation, analysis), qualitative interviews, systematic literature reviews, expert and stakeholder consultation, document analysis
Non-bioethics	Various methods in electrophysiology and molecular biology (patch clamp, intracellular potential measurements, Ussing chamber, PCR etc.), clinical quality management, archival research

## PUBLICATIONS

Google Scholar: h-index 36 (27 since 2019), i10-index 71 (50 since 2019), total number of citations >4000

## I) MONOGRAPHS

1) **Schulz-Baldes A:** *Der Mineralokortikoidrezeptor ist keine Voraussetzung für die Stimulierung des transepithelialen Na<sup>+</sup>-Transportes durch Glukokortikoide – Messungen an der Mineralokortikoidrezeptor Knock-out Maus*, Freiburg 2003 [MD/PhD thesis]. Available from: [www.freidok.uni-freiburg.de/volltexte/1125/pdf/doktora.pdf](http://www.freidok.uni-freiburg.de/volltexte/1125/pdf/doktora.pdf)

## II) EDITED BOOKS (\*peer-reviewed)

2)\* Fourie C, **Rid A** (Eds): *What is enough? Sufficiency, justice, and health*, Oxford University Press: Oxford, New York 2017

Reviews: *Journal of Medicine and Philosophy*, *Public Health Ethics*, *Journal of Bioethical Inquiry*

1) Biller-Andorno N, Schaber P, **Schulz-Baldes A** (Hrsg): *Gibt es eine universale Bioethik?*, Mentis: Paderborn 2008

Review: *Medicine, Health Care and Philosophy*

## III) EDITED JOURNAL ISSUES (\*peer-reviewed)

4)\* Shah SK, **Rid A** (Eds): The ethics of controlled human infection studies. *Bioethics* 2020; 34(8): 748-876

3)\* **Rid A**, Shah SK (Eds): Substantiating the social value requirement for research. *Bioethics* 2017; 31(2): 71-152

2)\* **Rid A** (Ed): Treatment decision making for incapacitated patients: Can and should we predict patients' preferences? *Journal of Medicine and Philosophy* 2014; 39(2): 99-204

1)\* **Rid A**, Biller-Andorno N (Eds): Mini symposium on Norman Daniels' „Just Health – Meeting health needs fairly” (with a reply by Norman Daniels). *Journal of Medical Ethics* 2009; 35(1): 1-41

## IV) REPORTS & GUIDELINES

5) The PHASES (Pregnancy and HIV/AIDS: Seeking Equitable Study) Working Group: *Ending the evidence gap for pregnant women around HIV & co-infections: A call to action*. Chapel Hill, NC: July 2020 [co-author, by Beigi R, Bekker LG, Chi B, Cohn S, Diallo DD, Eron J, Faden R, Kashuba A, Kasule M, Krubiner C, Little MO, Lyster AD, Mfutso-Bengo J, Mofenson L, Mwapasa V, Mworeko L, Myer L, Penazzato M, **Rid A**, Shapiro R, Singh J, Sullivan K, Vicari M, Wambui J, White A, Wolf L]

4) Council for International Organizations of Medical Sciences (in collaboration with the World Health Organization): *International Ethical Guidelines for Health-Related Research Involving Humans*. Geneva 2016 [co-author, by Bhan A, van Delden JJM, Gefenas E, van der Graaf R, Greco D, Haerry D, Kouyate B, London AJ, Macklin R, **Rid A**, Saracci R, Touré A]

3) World Health Organization: *Expert Consultation on the Use of Placebos in Vaccine trials*. Geneva 2013 [co-author, by Baqui A, Bhan A, Bines J, Caplan A, #Colgrove J, Dhali A, Gomez-Diaz RA, Green S, Kang G, Lagos R, London AJ, Mullholland K, Neels P, Pitisuttithum P, Pratt D, #**Rid A**, Sarr SC, Selgelid M, Sheehan M, Smith PG]

#Meeting rapporteurs

2) World Health Organization: *Guiding Principles on Human Cell, Tissue and Organ Transplantation*. Geneva 2010 [consultant]

1) Deutscher Bundestag: *Bericht der Enquete-Kommission Ethik und Recht der modernen Medizin - Über den Stand der Arbeit*. Berlin 2005 [scientific coordinator]

**V) JOURNAL ARTICLES** (\*peer-reviewed)

84)\* Shah SK, Ibrahim A, Hinga A, Vintimilla J, Jones M, **Rid A**, Eckstein L, Kamuya D: Ethical Issues Faced by Data Monitoring Committees: Results from an exploratory qualitative study. *Ethics & Human Research* (forthcoming)

83)\* Earl J, Dawson L, **Rid A**: The social value misconception in clinical research. *American Journal of Bioethics* (forthcoming)

82)\* Dubé K, Villa TJ, Freshwater W, Mauk B, **Rid A**, Peluso MJ: Partner Protections in HIV Cure-Related Trials Involving Analytical Treatment Interruption: Updated Toolkit to Mitigate HIV Transmission Risk. *Journal of Virus Eradication* 2024;10(3): 100386

81)\* Hinga A, Vintimilla J, Ibrahim A, Jones M, **Rid A**, Eckstein L, Shah SK, Kamuya D: Ethical Preparedness of Data Monitoring Committees (DMCs) to Oversee International Clinical Trials: A qualitative descriptive study. *BMJ Global Health* 2024; 9(8): e015233

80)\* Charlton V, DiStefano M, Mitchell P, Morrell L, Rand L, Badano G, Baker R, Calnan M, Chalkidou K, Culyer A, Howdon D, Hughes D, Lomas J, Max C, McCabe C, O'Mahony J, Paulden M, Pemberton-Whiteley Z, **Rid A**, Scuffham P, Sculpher M, Shah K, Weale A, Wester G: We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment. *Health, Economics, Policy and Law* 2024; 19(2): 153-173

79)\* Earp BD, Porsdam Mann S, Allen J, Salloch S, Suren V, Jongsma K, Braun M, Wilkinson D, Sinnott-Armstrong W, **Rid A**, Wendler D, Savulescu J: A personalized patient preference predictor for substituted judgments in healthcare: technically feasible and ethically desirable. *American Journal of Bioethics* 2024; 24(7): 13-36

Subject of an editorial, 15 open peer commentaries and a response (selection):

Blumenthal-Barby J, et al: Ethical Complexities in Utilizing Artificial Intelligence for Surrogate Decision Making. *American Journal of Bioethics* 2024; 24(7): 1-2

Berger JT: Artificial Intelligence, Digital Self, and the “Best Interests” Problem. *American Journal of Bioethics* 2024; 24(7): 27-29

Herington J, Kluger B: Parrots at the Bedside: Making Surrogate Decisions with Stochastic Strangers. *American Journal of Bioethics* 2024; 24(7): 32-34

Bishop JP: The Problematic “Existence” of Digital Twins: Human Intention and Moral Decision. *American Journal of Bioethics* 2024; 24(7): 45-47

78)\* **Rid A**, Aguilera B, Banda C, Divi R, Harris M, Kim A, Ossandon M, Zervos J, Rowthorne V: Global health reciprocal innovation: ethical, legal and regulatory considerations. *BMJ Global Health* 2024; 8: e014693

77)\* Dubé K, Morton T, Fox L, Dee L, Palm D, Villa TJ, Freshwater W, Taylor J, Graham G, Carter WB, Saucedo JA, Peluso MJ, **Rid A**: A Partner Protection Package (P3) for HIV Cure-Related Studies Involving Analytical Treatment Interruptions. *Lancet Infectious Diseases* 2023; 23(10): E418-E430

76)\* **Rid A**, Feld JJ, Liang TJ, Weijer C: The ethics of controlled human infection studies with hepatitis C virus. *Clinical Infectious Diseases* 2023; 77(Supplement\_3): S216-S223

75)\* Ricotta E, **Rid A**, Cohen GI, Evans N: Observational studies must be reformed before the next pandemic. *Nature Medicine* 2023; 29(8): 1903-1905

74)\* Sugarman J, Wenner DM, **Rid A**, Meltzer Henry L, Luna F, Klitzman R, MacQueen K, Rennie S, Singh JA, Gostin LO: Towards Ethical Research with People Who can become Pregnant when Abortion Access is legally restricted. *Science* 2023; 380 (6651): 1224-1226

73)\* Jardas E, Wesley R, Pavlick M, Wendler D, **Rid A**: Patients' priorities for surrogate decision-making: possible influence of misinformed beliefs. *AJOB Empirical Bioethics* 2022; 13(3): 137-151

72)\* Lyerly AD, Beigi R, Bekker LG, Chi BH, Cohn SE, Diallo DD, Eron J, Faden R, Jaffe E, Kashuba A, Kasule M, Krubiner C, Little M, Mfustso-Bengo J, Mofenson L, Mwapasa V, Mworeko L, Myer L, Penazzato M, **Rid A**, Shapiro R, Singh JA, Sullivan K, Vicari M, Wambui J, White A, Wickremshire M, Wolf L: Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project. *Journal of the International AIDS Society* 2021; 24: e25846

71)\* Iyer AA, Saade D, Bharucha-Goebel DX, Foley AR, Averion G, Paredes E, Gray S, Bonnemann CG, Grady C, Hendriks S, **Rid A**: Ethical challenges Ethical Challenges for a New Wave of Early-Phase Pediatric Gene Therapy Trials. *Genetics in Medicine* 2021; 23(11): 2057-2066

70)\* Eckstein L, **Rid A**, Kamuya D, Shah SK: The essential role of DSMBs in ensuring the ethics of global vaccine trials to address COVID-19. *Clinical Infectious Diseases* 2021; 11(1): 2126–2130

69) **Rid A**, Lipsitch M, Miller FG: The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials. *Journal of the American Medical Association* 2021; 325(3): 219-220

68)\* Strassle C, Jardas E, Ochoa J, Berkman BE, Danis M, **Rid A**, Taylor HA: COVID-19 vaccine trials and incarcerated populations—the ethics of inclusion. *New England Journal of Medicine* 2020; 383(20): 1897-1899

67)\* van der Graaf R, Macklin R, **Rid A**, Bhan A, Gefenas E, Greco D, Haerry D, Hurst S, London AJ, Saracci R, Sprumont D, van Delden JJM: Integrating public health programs and research after the Malaria Vaccine Implementation Program (MVIP): recommendations for next steps. *Vaccine* 2020; 38(45): 6975-6978

66)\* Grady C, Shah SK, Miller FG, Danis M, Nicolini M, Ochoa J, Taylor HA, Wendler D, **Rid A**. So much at stake: ethical trade-offs in accelerating SARS-CoV-2 vaccine development. *Vaccine* 2020; 38(41): 6381-6387

65)\* Vaswani V, Saxena A, Shah SK, Palacios R, **Rid A**: Informed consent for controlled human infection studies in low- and middle-income countries: ethical challenges and proposed solutions. *Bioethics* 2020; 34(8): 809-819

64)\* **Rid A**, Roestenberg M: Judging the social value of controlled human infection studies. *Bioethics* 2020; 34(8): 749-763

63) **Rid A**: Judging the social value of health-related research: current debate and open questions. *Perspectives in Biology and Medicine* 2020; 63(2): 293-312

62) Wild V, Buyx A, Hurst SA, Munthe C, **Rid A**, Strech D, Thompson A: COVID-19: Eine Ad-hoc Public-Health-Ethikberatung. *Das Gesundheitswesen* 2020; 82(06): 507-513

English version: Wild V, Buyx A, Hurst SA, Munthe C, **Rid A**, Strech D, Thompson A: Responding to the SARS-CoV-2 pandemic: Experiences of an *ad hoc* public health ethics consultation. *Journal of Medical Ethics blog*, April 1, 2020. Available at: <https://blogs.bmj.com/medical-ethics/2020/04/01/responding-to-the-sars-cov-2-pandemic-experiences-of-an-ad-hoc-public-health-ethics-consultation/>

61)\* Iyer AA, Hendriks S, **Rid A**: Advantages of using lotteries to select participants for high-demand COVID-19 treatment trials. *Ethics & Human Research* 2020; 42(4): 1-6

60)\* Shah SK, Miller FG, Darton TC, Duenas D, Emerson C, Fernandez-Lynch H, Jamrozik E, Jecker NS, Kamuya D, Kapulu M, Kimmelman J, MacKay D, Memoli MJ, Murphy SC, Palacios R, Ritchie TL, Roestenberg M, Saxena A, Saylor K, Selgelid MJ, Vaswani V, **Rid A**: Ethics of controlled human infection to address COVID-19. *Science* 2020; 368(6493): 832-34

Subject of a response: Eyal N: Unnecessary hesitancy on human vaccine tests. *Science* 2020; 369(6500): 150-151

59)\* Aguilera B, DeGrazia D, **Rid A**: Regulating international clinical research: an ethical framework for policy-makers. *BMJ Global Health* 2020; 5:e002287

58)\* Rumbold B, Charlton V, **Rid A**, Mitchell P, Wilson J, Littlejohns P, Max C, Weale A: Affordability and non-perfectionism in moral action. *Ethical Theory and Moral Practice* 2019; 22(4): 973-91

57)\* **Rid A**, Littmann J, Buyx A: Evaluating the risks of public health programs: rational antibiotic use and antimicrobial resistance. *Bioethics* 2019; 33(7): 734-748

56)\* Charlton V, **Rid A**: Innovation as a value in healthcare priority-setting: The UK experience. *Social Justice Research* 2019; 32(2): 208-38

55) Littlejohns P, Chalkidou K, Culyer AJ, Weale A, **Rid A**, Kieslich K, Coultas C, Max C, Manthorpe J, Rumbold B, Charlton V, Roberts H, Faden R, Wilson J, Krubiner C, Mitchell P, Wester G, Whitty JA, Knight S: National Institute for Health and Care Excellence, social values and healthcare priority setting. *Journal of the Royal Society of Medicine* 2019; 112(5): 173-179

54)\* Kahn R, **Rid A**, Smith PG, Eyal N, Lipsitch M: Choices in vaccine trial design in epidemics of emerging infections. *PLoS Medicine* 2018; 15(8): e1002632

53)\* Ives J, Dunn M, Molewijk B, Schildmann J, Bærøe K, Frith L, Huxtable R, Landeweer E, Mertz M, Provoost V, **Rid A**, Salloch S, Sheehan M, Strech D, de Vries M, Widdershoven G: Standards of Practice in Empirical Bioethics Research: Towards a Consensus. *BMC Medical Ethics* 2018; 19: 68

Subject of two commentaries and a response: Carter S: Debating diversity: a commentary on “Standards of Practice in Empirical Bioethics Research”. *BMC Medical Ethics* 2018; 19: 67

Cribb A: Let’s talk about standards. *BMC Medical Ethics* 2018; 19: 69

Dunn M, Ives J, Molewijk B, Schildmann J: Setting standards for empirical bioethics research: a response to Cribb and Carter. *BMC Medical Ethics* 2018; 19: 66

52)\* Littmann J, **Rid A**, Buyx AM: Tackling anti-microbial resistance: ethical framework for rational antibiotic use. *European Journal of Public Health* 2018; 28(2): 359-363

Extended version: Littmann J, **Rid A**, Buyx AM: Tackling antimicrobial resistance: an ethical framework for rational antibiotic use. In: Jamrozik E, Selgelid M (Eds): *Ethics and Drug Resistance: Collective Responsibility for Global Public Health*. Springer: Dordrecht 2020; pp. 321-344

51) #Hey SP, London AJ, Weijer C, #**Rid A**, Miller FG: Is the concept of clinical equipoise still relevant to research? *British Medical Journal* 2017; 359: j5787 [invited “Head to Head” contribution, #first authors]

50)\* Rumbold B, Baker R, Ferraz O, Hawkes S, Krubiner C, Littlejohns P, Norheim OF, Pegram T, **Rid A**, Venkatapuram S, Voorhoeve A, Wang D, Weale A, Wilson J, Yamin AE, Hunt P: Universal Health Coverage, Priority Setting and the Human Right to Health. *Lancet* 2017; 390(10095): 712–714

49)\* Charlton V, Littlejohns P, Kieslich K, Mitchell P, Rumbold B, Weale A, Wilson J, **Rid A**: Cost-effective but unaffordable? An increasing challenge for health systems. *British Medical Journal* 2017; 356: j1402

48)\* Rumbold B, Weale A, **Rid A**, Wilson J, Littlejohns P: Public Reasoning and Health Care Priority Setting: The Case of NICE. *Kennedy Institute of Ethics Journal* 2017; 27(1): 107-134

47)\* Wendler D, **Rid A**: In defense of the social value requirement for clinical research. *Bioethics* 2017; 31(2): 77-86

46)\* Wendler D, Wesley R, Pavlick M, **Rid A**: Do Patients Want their Families or their Doctors to Make Treatment Decisions in the Event of Incapacity, and Why? *American Journal of Bioethics - Empirical Bioethics* 2016; 7(4): 251-259

45)\* Cassel JB, Del Fabbro E, Arkenau T, Higginson IJ, Hurst S, Jansen LA, Poklepovic A, **Rid A**, Rodón J, Strasser F, Miller FG: Phase I cancer trials and palliative care: Antagonism, irrelevance, or synergy? *Journal of Pain and Symptom Management* 2016; 52(3):437-45

44)\* Kieslich K, Ahn J, Badano G, Chalkidou K, Cubillos L, Curi R, Krubiner C, Littlejohns P, Lu L, Pearson S, **Rid A**, Weale A, Whitty J, Wilson J: Public Participation in Decision-Making



on the Coverage of New Antivirals for Hepatitis C. *Journal of Health Organization and Management* 2016; 30(5):769-85

43)\* Dal-Ré R, **Rid A**, Emanuel EJ, Wendler D: The potential exploitation of research participants in high income countries who lack access to health care. *British Journal of Clinical Pharmacology* 2016; 81: 857–864

42) Littlejohns P, Weale A, Kieslich K, Wilson J, Rumbold B, **Rid A**: Challenges for the new Cancer Drugs Fund. *Lancet Oncology* 2016; 17(4): 416–418

41)\* Charles A, **Rid A**, Davies H, Draper H: Prisoners as research participants: Current practice and attitudes in the UK. *Journal of Medical Ethics* 2016; 42(4): 246-252

40)\* Vayena E, Brownsword R, Edwards SJ, Greshake B, Kahn J, Ladher N, Montgomery J, O'Connor D, O'Neill O, Richards MP, **Rid A**, Sheehan M, Wicks P, Tasioulas J: Research led by participants: a new social contract for a new kind of research. *Journal of Medical Ethics* 2016; 42(4): 216-219

39)\* Wendler D, Wesley R, Pavlick M, **Rid A**: A New Method for Making Treatment Decisions for Incapacitated Patients: What do Patients Think about the Use of a Patient Preference Predictor? *Journal of Medical Ethics* 2016; 42(4): 235-241

38)\* Johnson R, **Rid A**, Emanuel EJ, Wendler D: Risks of phase 1 research with healthy participants: A systematic review. *Clinical Trials* 2016; 13(2):149-60

37)\* **Rid A**, Miller FG: Ethical rationale for the Ebola “ring vaccination” trial design. *American Journal of Public Health* 2016; 106(3):432-5

Subject of a response: Haire BG, Folyan MO (2016): Ebola 'ring' vaccine trial was ethically innovative. *American Journal of Public Health* 106 (9): e1-e1

36)\* Racine E, Jox RJ, Bernat JL, Dabrock P, Gardiner D, Marckmann G, **Rid A**, Rodriguez-Arias D, in der Schmitt J, Schöne-Seifert B: Determination of death: A discussion on responsible scholarship, clinical practices, and public engagement. *Perspectives in Biology and Medicine* 2015; 58(4): 444-465

35)\* **Rid A**, Littlejohns P, Wilson J, Rumbold B, Kieslich K, Weale A: The importance of being NICE. *Journal of the Royal Society of Medicine* 2015; 108(10): 385-389

34)\* **Rid A**, Wesley R, Pavlick M, Maynard S, Roth K, Wendler D: Patients' priorities for treatment decision-making during periods of incapacity: Quantitative survey. *Palliative & Supportive Care* 2015; 13(5): 1165-83

33)\* Emanuel EJ, Bedarida G, Macci K, Gabler NB, **Rid A**, Wendler D: Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. *British Medical Journal* 2015; 350: h3271

Subject of an editorial and two responses: Kimmelman J: The secret realm of phase I trials in healthy volunteers. *British Medical Journal* 2015; 350: h3444

Brendish NJ, Gbesemete DF, de Graaf H, Edwards CJ, Faust SN: Phase I studies:

the role of publicly funded academic-healthcare partnerships. *British Medical Journal* 2015; 351: h3889

van den Borgert CA, Cohen AF: Need for a proactive and structured approach to risk analysis when designing phase I trials. *British Medical Journal* 2015; 351: h3899

32)\* Bromwich D, **Rid A**: Can informed consent to research be adapted to risk? *Journal of Medical Ethics* 2015; 41(7): 521-528 [open access as editor's choice]

31)\* Wendler D, **Rid A**: Genetic research on biospecimens poses minimal risk. *Trends in Genetics* 2015; 31(1):11-15

30)\* **Rid A**, Emanuel EJ: Ethical considerations of experimental interventions in the Ebola outbreak. *Lancet* 2014; 384(9957): 1896-1899 [with podcast]

Subject of two responses: Folayan M, Brown B, Yakubu A, Peterson K, Haire B: Compassionate use of experimental drugs in the Ebola outbreak. *Lancet* 2014; 384(9957): 1843

Jacob ST, Crozier I, Schieffelin JS, Colebunders R: Priorities for Ebola virus Disease response in west Africa. *Lancet* 2014; 384(9957): 1843-1844

29)\* **Rid A**: Setting risk thresholds in research: Lessons from the debate about minimal risk. *Monash Bioethics Review* 2014; 32(1): 63-85 [selected for special inaugural issue to mark the journal's relaunch with Springer]

28)\* **Rid A**, Emanuel EJ: Why should high-income countries help combat Ebola? *Journal of the American Medical Association* 2014; 312(13): 1297-1298

27)\* **Rid A**: How should we regulate risk in biomedical research? An ethical analysis of recent policy proposals and initiatives. *Health Policy* 2014; 117(3): 409-420

26)\* **Rid A**, Abdoler E, Roberson-Nay R, Pine SD, Wendler D: Evaluating the risks of clinical research: Direct comparative analysis. *Journal of Child and Adolescent Psychopharmacology* 2014; 24(7): 390-8

25)\* **Rid A**, Saxena A, Baqui AH, Bhan A, Bines J, Bouesseau MC, Caplan A, Colgrove J, Dhali A, Gomez-Diaz R, Green SK, Kang G, Lagos R, Loh P, London AJ, Mulholland K, Neels P, Pitisuttithum P, Sarr SC, Selgelid M, Sheehan M, Smith PS: Placebo use in vaccine trials: recommendations of a WHO expert panel. *Vaccine* 2014; 32(37): 4708-12

Subject of a commentary and response: Greenwood B: The use of placebo in vaccine trials. *Lancet* 2014; 383(9935): 2101-2102

Byberg S, Benn CS: Placebo use in vaccine trials: Caution when using active vaccines as placebo. *Vaccine* 2017; 35(9): 1211

24)\* **Rid A**, Wendler D: Use of a *Patient Preference Predictor* to help make medical treatment decisions for incapacitated patients. *Journal of Medicine and Philosophy* 2014; 39(2): 104-129 [open access as editor's choice]

23)\* **Rid A**, Wendler D: Treatment decision making for incapacitated patients: Is development and use of a *Patient Preference Predictor* feasible? *Journal of Medicine and Philosophy* 2014; 39(2): 130-152 [open access as editor's choice]

Subject of a special issue with six replies:

Brock D: Reflections on the *Patient Preference Predictor*. *Journal of Medicine and Philosophy* 2014; 39(2), 153-160

Lindemann H, Lindemann Nelson J: The Surrogate's Authority. *Journal of Medicine and Philosophy* 2014; 39(2), 161-168

John S: *Patient Preference Predictors*, Apt Categorisation and Respect for Autonomy. *Journal of Medicine and Philosophy* 2014; 39(2), 169-177

Dresser R: Law, Ethics and the *Patient Preference Predictor*. *Journal of Medicine and Philosophy* 2014; 39(2), 178-186

Kim S: Improving Medical Decisions for Incapacitated Patients: Does Focusing on 'Accurate Predictions' Lead to an Inaccurate Picture? *Journal of Medicine and Philosophy* 2014; 39(2), 187-195

Ditto P, Clark CJ: Predicting End-of-Life Treatment Preferences: Perils And Practicalities. *Journal of Medicine and Philosophy* 2014; 39(2), 196-204

Subject of a response with commentaries: Sharadin N: Patient Preference Predictors and the Problem of Naked Statistical Evidence. *Journal of Medical Ethics* 2018 (online early)

22)\* Abdul-Karim R, Berkman BE, Wendler D, **Rid A**, Khan J, Badgett T, Hull SC: Disclosure of Incidental Findings from Next Generation Sequencing in Pediatric Genomic Research. *Pediatrics* 2013; 131: 564-571

21)\* Monteverde S, **Rid A**: Controversies in the determination of death: perspectives from Switzerland. *Swiss Medical Weekly* 2012; 142: w13667

20)\* Kelly B, **Rid A**, Wendler D: Systematic Review: Individuals' Goals for Surrogate Decision Making. *Journal of the American Geriatrics Society* 2012; 60(5): 884-95

19)\* **Rid A**, Wendler D: A Proposal and Prototype for a *Research Risk Repository* to Improve the Protection of Research Participants. *Clinical Trials* 2011; 8: 705-715

Subject of an editorial: Botkin J: The value of evidence-based risk assessments. *Clinical Trials* 8: 685-686

18)\* **Rid A**, Wendler D: A Framework for Risk-Benefit Evaluations in Biomedical Research. *Kennedy Institute of Ethics Journal* 2011; 21(2): 141-179

Included in: World Health Organization, Department of Ethics, Equity, Trade, and Human Rights: *WHO Research Ethics Online Training*

17)\* Wendler D, **Rid A**: Systematic Review: The Effect on Surrogates of Making Treatment Decisions for Others. *Annals of Internal Medicine* 2011; 154(5): 336-46

16)\* **Rid A**, Emanuel EJ, Wendler D: Evaluating the Risks of Clinical Research. *Journal of the American Medical Association* 2010; 304(13): 1472-79

Subject of a response: Rossi J, Nelson RM: Is there an objective way to compare research risks? *Journal of Medical Ethics* 2012; 38: 423-427

15)\* **Rid A**, Wendler D: Can we improve medical treatment decision-making for incapacitated patients? *Hastings Center Report* 2010; 40(5): 36-45

14)\* **Rid A**, Wendler D: Risk-benefit assessment in medical research – critical review and open questions. *Law, Probability and Risk* 2010; 9(3-4): 151-177

13)\* **Rid A**, Schmidt H: The 2008 Declaration of Helsinki: first among equals in research ethics? *Journal of Law, Medicine and Ethics* 2010; 38(1): 143-148

12)\* **Rid A**, Schmidt H: Die erneut überarbeitete “Deklaration von Helsinki”: wie sind die Änderungen aus ethischer Sicht zu beurteilen? *Deutsche Medizinische Wochenschrift* 2009; 134(49): 2525-2528

Reprinted in: Ehni H-J, Wiesing U (Hrsg.): *Die Deklaration von Helsinki: Revisionen und Kontroversen*, Deutscher Ärzteverlag: Köln 2012, pp. 25-31

11)\* **Rid A**, Bachmann L, Wettstein V, Biller-Andorno N: Would you sell a kidney in a regulated kidney market? Results of an exploratory study. *Journal of Medical Ethics* 2009; 35(9): 558-564

10)\* **Rid A**: Justice and Procedure: How does “accountability for reasonableness” result in fair limit-setting decisions? *Journal of Medical Ethics* 2009; 35(1): 12-16

Subject of a response: Daniels N: Just health: replies and further thoughts. *Journal of Medical Ethics* 2009; 35(1): 36-41

German translation: **Rid A**: Faire Allokationsprozesse: zum Verhältnis von substantieller und prozeduraler Gerechtigkeit in Norman Daniels’ Just Health. In: Strech D, Marckmann G (Hrsg): *Public Health Ethik*, LIT Verlag: Münster 2009, pp. 159-174

Short version (in German): **Rid A**: Faire Entscheidungsprozesse und Gerechtigkeit in der Gesundheitsversorgung: das Beispiel von Norman Daniels’ *Accountability for Reasonableness*. *Gesundheits- und Sozialpolitik* 2012; 2: 14-20

9) \*Obladen M, Metze B, Henrich W, Aktas A, Czernik C, **Schulz-Baldes A**: Interdisciplinary Surveillance of Periventricular Hemorrhage Associated Conditions In Infants <1000 g. *Acta Paediatrica* 2008; 97(6): 731-737

8)\* **Schulz-Baldes A**, Biller-Andorno N, Capron AM: International perspectives on the ethics and regulation of human cell and tissue transplantation. *WHO Bulletin* 2007; 85(12): 941-948

Subject of an editorial: Noel L: Current concerns in transplantation. *WHO Bulletin*

2007; 85(12): 905

7)\* **Schulz-Baldes A**, Delmonico FD: Improving Institutional Fairness to Live Kidney Donors: Donor Needs must Be Addressed By Safeguarding Donation Risks and Compensating Donation Costs. *Transplant International* 2007; 20(11): 940-946

6)\* **Schulz-Baldes A**, Huseman D, Loui A, Dudenhausen J, Obladen M: Neonatal end-of-life practice in a German perinatal centre. *Acta paediatrica* 2007; 96(5): 681-687

5) **Schulz-Baldes A**, Vayena E, Biller-Andorno N: Sharing benefits in international health research. Research-capacity building as an example of an indirect collective benefit. *EMBO Reports* 2007; 8(1): 8-13

4)\* Goldschmidt I, Grahammer F, Warth R, **Schulz-Baldes A**, Garty H, Greger R, Bleich M: Kidney and colon electrolyte transport in CHIF knockout mice. *Cellular Physiology and Biochemistry* 2004; 14(1-2): 113-120

3)\* **Schulz-Baldes A**, Berger S, Grahammer F, Warth R, Goldschmidt I, Peters J, Schütz G, Greger R, Bleich M: Induction of the epithelial Na<sup>+</sup> sodium channel via glucocorticoids in mineralocorticoid receptor knockout mice. *Pfluegers Archiv - European Journal of Physiology* 2001; 443: 297-305

2)\* Hasselblatt P, Warth R, **Schulz-Baldes A**, Greger R, Bleich M: pH regulation in isolated in vitro perfused rat colonic crypts. *Pfluegers Archiv - European Journal of Physiology* 2000; 441(1): 118-124

1)\* Bleich M, Warth R, Schmidt-Hieber M, **Schulz-Baldes A**, Hasselblatt P, Fisch D, Berger S, Kunzelmann K, Kriz W, Schütz G, Greger R: Rescue of the mineralocorticoid receptor knockout mouse. *Pfluegers Archiv - European Journal of Physiology* 1999; 438: 245-254

## VI) BOOK CONTRIBUTIONS

15) **Rid A**: Ethical evaluation of research risks and potential benefits. In: Iltis AS, MacKay D (Eds): *The Oxford Handbook of Research Ethics*. Oxford University Press: Oxford, New York 2023; pp. Pages C11S1–C11N11.

14) **Rid A**, Antierens A: How did Médecins Sans Frontières negotiate clinical trials of unproven treatments during the 2014-15 Ebola epidemic? In: Hofmann M, Au S (Eds): *Ebola: The Politics of Fear: Médecins Sans Frontières and the West African Ebola Epidemic*. Oxford University Press: Oxford, New York 2017; pp. 129-170

French translation: **Rid A**, Antierens A: Comment Médecins Sans Frontières a-t-elle négocié les essais cliniques de traitements non homologués pendant l'épidémie d'Ebola de 2014-2015? In: Hofmann M, Au S (Eds): *La Politique de la Peur: Médecins Sans Frontières et l'Épidémie d'Ebola*. Renaissance du Livre: Bruxelles 2017; pp. 185-235

13) **Rid A**: (How) should experimental vaccines and treatments for Ebola be used? In: Evans NG, Smith TC, Majumder MS (Eds): *Ebola's Message: Public Health and Medicine in the Twenty-First Century*. MIT Press: Cambridge 2017; pp. 183-200

- 12) **Rid A**: Sufficiency, health, and health care justice: The state of the debate. In: Fourie C, Rid A (Eds): *What is enough? Sufficiency, justice, and health*. Oxford University Press: Oxford, New York 2017; pp. 30-47.
- 11) **Rid A**: Rethinking risk-benefit evaluations in biomedical research. In: Strech D, Mertz M (Eds): *Ethics and Governance of Biomedical Research: Theory and Practice*. Springer: Dordrecht, Heidelberg, London, New York 2016; pp. 153-162
- 10) van der Graaf R, **Rid A**: Placebo-controlled trials, ethics of. In: Wright JD (Ed): *International Encyclopedia of the Social & Behavioral Sciences*, 2<sup>nd</sup> Edition, Volume 18, Elsevier: Oxford, 2015, pp. 164-173
- 9) **Rid A**: Risk and Risk-Benefit Evaluations in Biomedical Research. In: Roeser S, Hillerbrand R, Sandin P, Peterson M (Eds): *Handbook of Risk Theory. Epistemology, Decision Theory, Ethics and Social Implications of Risk*, Springer: Dordrecht, Heidelberg, London, New York 2012, pp. 179-212
- 8) **Rid A**, Shah SK: The ethics of international research: The Constant Gardener. In: Colt H, Quadrelli S, Friedman L (Eds): *The Picture of Health: Medical Ethics and the Movies*, Oxford University Press: New York 2011, pp. 302-307
- 7) **Rid A**: Ethik an der Weltgesundheitsorganisation. In: Deutscher Akademischer Austauschdienst (Hrsg): *Prägende Einblicke. Alumni des Carlo-Schmid-Programms berichten über ihre Praktika in Internationalen Organisationen und EU-Institutionen. Ein Lesebuch*, Bundesministerium für Bildung und Forschung: Bonn 2010, pp. 146-163
- 6) **Rid A**, Dinhofer L: Consent. In: Warwick R, Fehily D, Brubaker SA, Eastlund T (Eds): *Tissue and Cell Donation: An Essential Guide*, Blackwell Publishing: Malden, MA, Oxford, Victoria 2009, pp. 67-97
- 5) **Schulz-Baldes A**: How political is the future of health care? Allocating scarce resources in liberal democracy. In: Elm S, Willich SN (Eds): *Quo Vadis Medical Healing? Past Concepts and New Approaches*, Springer: Berlin, Heidelberg, New York 2009, pp. 3-18
- 4) **Schulz-Baldes A**: Brauchen wir eine kulturübergreifende Bioethik? Das Beispiel internationaler Forschungskollaborationen. In: Biller-Andorno N, Schaber P, Schulz-Baldes A (Eds): *Gibt es eine universale Bioethik?* Mentis: Paderborn 2008, pp. 27-44
- 3) **Schulz-Baldes A**: Therapiebegrenzung in der Neonatologie: Entscheidungen im besten Interesse des Kindes? In: Schildmann J, Fahr U, Vollmann J (Eds): *Entscheidungen am Lebensende in der modernen Medizin: Ethik, Recht, Ökonomie und Klinik*, LIT Verlag: Münster 2006, pp. 91-110
- 2) **Schulz-Baldes A**, Misselwitz B, Metze B, Obladen M: 6 Jahre Berliner Neonatalerhebung: Entwicklungen in Gesamtberlin seit 1998. Eine Gegenüberstellung der Zeiträume 1998-2000 und 2001-2003. In: Ärztekammer Berlin: *Projekte 2005. Qualitätssicherung und Qualitätsmanagement*, Ärztekammer Berlin: Berlin 2005, pp. 17-40
- 1) **Schulz-Baldes A**: Das Jahr 1933. Die Medizinische Fakultät und die „Gleichschaltung“ an der Universität Freiburg. In: Grün B, Hofer H-G, Leven K-H (Eds): *Medizin und*

*Nationalsozialismus. Die Freiburger Medizinische Fakultät und das Klinikum in der Weimarer Republik und im „Dritten Reich“*, Peter Lang: Frankfurt 2002, pp. 139-160

## VII) COMMENTARIES, EDITORIALS, LETTERS, BOOK REVIEWS ETC.

29) Shah SK, Kusma J, **Rid A**: Ethics of Global Health Research involving Children and Adolescents. In: Section on Bioethics, American Academy of Pediatrics. Diekema DS, Leuthner SR, Vizcarrondo FE, eds. *American Academy of Pediatrics Bioethics Resident Curriculum: Case-Based Teaching Guides*. Revised 2023. Available at: (forthcoming)

28) **Rid A**: Foreword. In: Obladen, M: *Oxford Textbook of The Newborn: A Cultural and Medical History*. Oxford University Press: Oxford, New York 2021 [invited preface]

28)\* **Rid A**, Shah SK, Miller FG, Danis M, Nicolini M, Ochoa J, Taylor HA, Wendler D, Grady C. So much at stake: ethical trade-offs in accelerating SARS-CoV-2 vaccine development—Response to Gurwitz. *Vaccine* 2021; 39(7): 1028-1029 [invited reply]

27) Shah SK, **Rid A**: The ethics of controlled human infection studies: Past, present and future. *Bioethics* 2020; 34(8): 745-748 [editorial]

26) Shah SK, Miller FG, Darton TC, Duenas D, Emerson C, Fernandez-Lynch H, Jamrozik E, Jecker NS, Kamuya D, Kapulu M, Kimmelman J, MacKay D, Memoli MJ, Murphy SC, Palacios R, Ritchie TL, Roestenberg M, Saxena A, Saylor K, Selgelid MJ, Vaswani V, **Rid A**. Unnecessary hesitancy on human vaccine tests—Response. *Science* 2020; 369(6500): 151 [invited reply]

25) van der Graaf R, Macklin R, **Rid A**, Bhan A, Gefenas E, Greco D, Haerry D, Hurst S, London AJ, Saracci R, Sprumont D, van Delden JJM: Integrating public health programs and research and the CIOMS guidelines. *British Medical Journal* 2020; 368: m734 [rapid response]

24) Iyer AA, Hendriks S, **Rid A**: The challenge of selecting participants fairly in high-demand trials. *American Journal of Bioethics* 2020; 20(2): 35-38 [peer commentary]

23) **Rid A**: The next wave in healthcare priority-setting. *Hasting Center Report* 2018; 48(4): inside front cover [invited commentary]

22) **Rid A**: Individual and public interests in clinical research during epidemics: a reply to Calain. *Journal of Medical Ethics* 2018; 4: 11-12 [invited commentary]

21) **Rid A**, Shah SK: Substantiating the social value requirement for research: an introduction. *Bioethics* 2017; 31(2): 72-76 [editorial]

20) Fourie C, **Rid A**: Introduction. In: Fourie C, Rid A (Eds): *What is enough? Sufficiency, justice and health*, Oxford University Press: Oxford, New York 2017; pp. 1-8 [editorial]

19) The PLOS Medicine Editors, **Rid A**, Johansson MA, Leung G, Valentine H, Burchard EG, Oh SS, Zimmerman C: Towards Equity in Health: Researchers Take Stock. *PLoS Med* 2016; 13(11): e1002186 [invited contribution to the PLoS Medicine end-of-year editorial]

- 18)\* Dal-Ré R, **Rid A**, Emanuel EJ, Wendler D: Addressing exploitation of poor clinical trial participants in North America and the European Union. *European Journal of Internal Medicine* 2016; 34: e36-e37 [letter]
- 17) **Rid A**: The goals of research during an epidemic. *American Journal of Bioethics* 2015; 15(4): 47-51 [invited commentary]
- 16) **Rid A**, Emanuel EJ: Compassionate use of experimental drugs in the Ebola outbreak – Authors’ reply. *Lancet* 2014; 384(9957): 1844 [invited reply]
- 15) **Rid A**: Will a *Patient Preference Predictor* Improve Treatment Decision-Making for Incapacitated Patients? *Journal of Medicine and Philosophy* 2014; 39(2): 99-103 [editorial]
- 14) **Rid A**, Monteverde S: Controversies in the determination of death—Note of clarification. *Swiss Medical Weekly* 2013; 143: w13782 [invited reply]
- 13) **Rid A**: What makes research socially valuable? Lessons from the Bucharest Early Intervention Study. *Journal of Nervous and Mental Disease* 2012; 200(3): 248-9 [invited commentary]
- 12) Krones T, Rüegg CA, Günthard HF, **Rid A**, Wild V: Kommentar I zum Fall: „Heimlicher Transfer von HIV-Medikamenten nach Afrika“. *Ethik in der Medizin* 2012; 24(1): 59-61 [invited commentary]
- 11) **Rid A**: Joachim Boos / Reinhard Merkel / Heiner Raspe / Bettina Schöne-Seifert (Hrsg.): Nutzen und Schaden aus klinischer Forschung am Menschen. Abwägung, Equipoise und normative Grundlagen. Deutscher Ärzteverlag, 2009. *Ethik in der Medizin* 2010; 22(2): 167-8
- 10) **Rid A**, Biller-Andorno N: Justice in Action? Introduction to the Mini Symposium on Norman Daniels’ “Just Health – Meeting Health Needs Fairly”. *Journal of Medical Ethics* 2009; 35(1): 1-2 [editorial]
- 9) **Rid A**: Bonnie Steinbock (Ed.): 2007, *The Oxford Handbook of Bioethics*, Oxford, New York: Oxford University Press. *Medicine, Health Care and Philosophy* 2008; 11(4): 489 [invited book review]
- 8) **Rid A**: Norman Daniels: 2008, *Just Health – Meeting health needs fairly*, Cambridge: Cambridge University Press. *WHO Bulletin* 2008; 86(8): 653 [invited book review]
- 7) **Rid A**: Peter A. Singer / Adrian M. Viens (Eds.): 2008, *The Cambridge Textbook of Bioethics*, Cambridge: Cambridge University Press. *Critical Care Medicine* 2008; 36 (8): 2492-2493 [invited book review]
- 6) **Schulz-Baldes A**: Loretta M. Kopelman: 2006, *Research with children. Access vs. protection*, Oxford, New York: Oxford University Press. *Medicine, Health Care and Philosophy* 2008; 11(2): 244-245 [invited book review]
- 5) **Schulz-Baldes A**, Biller-Andorno N, Schaber P: Einführung. In: Biller-Andorno N, Schaber P, Schulz-Baldes A (Hrsg.): *Gibt es eine universale Bioethik?*, Mentis: Paderborn 2008, pp. 9-23 [editorial]



4) Schmidt H, **Schulz-Baldes A**: The 2007 draft Declaration of Helsinki – Plus ça Change...? *Hastings Center Bioethics Forum*, November 28, 2007. Available at: <http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=666> (accessed on Jan 17, 2012)

3) **Schulz-Baldes A**: Margaret E. Mohrmann: 2005, *Attending Children. A doctor's education*, Washington, D.C.: Georgetown University Press. *Medicine, Health Care and Philosophy* 2007; 10: 349 [invited book review]

2) **Schulz-Baldes A**, Jakovljević A-K: Zur Möglichkeit einer kulturübergreifenden Bioethik. Interdisziplinärer Workshop des Lehrstuhls für Biomedizinische Ethik und der Arbeits- und Forschungsstelle für Ethik in Kooperation mit der Jungen Akademie der Berlin-Brandenburgischen Akademie der Wissenschaften und Akademie der Naturforscher Leopoldina, Ethik-Zentrum der Universität Zürich, 30. März bis 1. April 2006, *Ethik in der Medizin* 2006; 18(3): 261-266

1) **Schulz-Baldes A**, Splett T: Entscheidungen am Lebensende in der Modernen Medizin: Ethik, Recht, Ökonomie und Klinik. Interdisziplinäres Kolloquium des Instituts für Medizinische Ethik und Geschichte der Medizin für Nachwuchswissenschaftler und -wissenschaftlerinnen, Ruhr-Universität Bochum, 13.-17. Februar 2006, *Ethik in der Medizin* 2006; 18(2):195-200

#### PRESENTATIONS (selection)

Academic	Harvard University, Stanford University, National Institutes of Health, University of Oxford, London School of Economics, King's College London, University of Zurich, Université de Geneve, Université Pierre et Marie Curie, Charité Berlin, Ludwigs-Maximilian University Munich
Outreach	World Health Organization, World Medical Association, Swiss Ministry of Health, U.K. Health Research Authority, New York Academy of Medical Sciences
International conferences	International Association of Bioethics, American Society for Bioethics and Humanities, Society of Applied Philosophy, European Society for Philosophy of Medicine and Healthcare, European Society of Medical Oncology, European Forum for Good Clinical Practice, Public Responsibility in Medicine and Research (PRIM&R), International Society of Organ Donation and Procurement

#### GRANTS FOR RESEARCH (PI unless otherwise noted)

2021 – ...	Greenwall Foundation, Making a Difference in Real-World Bioethics Dilemmas Program (Ethics in the Interim: Learning from the COVID-19 pandemic to develop ethical guidance for data and safety monitoring committees overseeing clinical trials, Co-PI, with D. Kamuya, L. Eckstein, J. Kimmelman & S.K. Shah; \$219,685)
2016 – ...	Wellcome Trust, Society & Ethics Studentship (The influence of social values on NICE technology appraisal: an empirical ethics study; £93'675) – <i>Economic &amp; Social Research Council Doctoral Studentship of £58'140 awarded but declined</i>

- 2017 – 2019 Greenwall Foundation, Making a Difference in Real-World Bioethics Dilemmas Program (A new ethical and regulatory framework for the use of human challenge studies on emerging infectious diseases, Co-PI, with R.P. Gomez & S.K. Shah; \$199'117)
- 2018 King's College London, Faculty of Social Science & Public Policy Research Fund (Humanitarian principles and health research during humanitarian emergencies: a pilot study; £9'815)
- 2017 – 2018 King's College London, Multi- & Interdisciplinary Research Scheme (The right to health and sustainable development goals: lessons from Brazil, Co-PI, with O. Ferraz; £20'000)
- 2016 – 2018 Wellcome Trust, Seed Award (Towards A Humanitarian Research Ethics; £49'608)
- 2015 – 2016 Médecins Sans Frontières, Ebola Reflection Project (Unproven humanitarian assistance; travel grant)
- 2013 – 2015 European Commission, Marie Curie Fellowship (ETHICAL RISK: An ethical framework for the "risk-based" regulation of biomedical research; €209'000)
- 2012 – 2013 University of Zurich, Research Fellowship (Systematic Evaluation of Research Risks; CHF 51'100)
- 2012 – 2013 University of Konstanz, Institute of Advanced Study (The Ethics of Risk in Biomedical Research; €36'500 – partially accepted)
- 2011 – 2012 Swiss Academy of Medical Sciences (Risk-based Regulation of Biomedical Research: Ethical Considerations; CHF 20'000)
- 2010 – 2011 Swiss Academy of Medical Sciences (Minimal Risk in Clinical Research; CHF 45'000)
- 2010 – 2011 National Institutes of Health, Department of Bioethics (Risks of Phase 1 Research with Healthy Volunteers, Co-PI with E. Emanuel & D. Wendler; ~\$25'000)
- 2008 – 2011 National Institutes of Health, Department of Bioethics (Patients' Views on Surrogate Decision-Making, Co-PI with D. Wendler; ~\$15'000)
- 2007 – 2010 Swiss National Science Foundation, Fellowship for Advanced Researchers (Risk-benefit assessment in biomedical research; \$116'500)

**GRANTS FOR TEACHING** (PI unless otherwise noted)

2014 – 2015

King's College London, Faculty of Social Science & Public Policy  
(Medical London Excursions for Students; £5'000)

2013 King's College London, Worldwide Office (International scoping trip  
for the Bioethics & Society programme; £750)

**GRANTS FOR WORKSHOPS & MEETINGS (PI unless otherwise noted)**

2017 University of Oxford, ETHOX Centre (Ethical Design of Vaccine Trials  
in Emerging Infections, Co-PI with N. Eyal, M. Lipsitch, & R. Kahn;  
£12'500)

2017 King's College London, Faculty of Social Science & Public Policy  
Impact Fund (Social, scientific and ethical implications of policy  
initiatives to accelerate the development and marketing of medicines in  
Europe and the UK, Co-PI with C. Davis; ~£2'800)

2016 Economic and Social Research Council, Transformative Research  
Fellowship & Wellcome Trust, Small Grant (The ethics of research  
during an epidemic: Lessons from Ebola; £20'250)

2015 Wellcome Trust, Small Grant (Risk-adapted approaches to regulating  
research: ethical challenges; £5'000)

2012 Swiss National Science Foundation & Corti Foundation (The relevance  
of sufficiency for just health care, Co-PI with C. Fourie & A. Leist;  
CHF 10'000)

2009 National Institutes of Health, Department of Bioethics & Foundation for  
NIH (Systematic evaluation of research risks, Co-PI with E. Emanuel &  
D. Wendler; ~\$95'000)

2007 University of Zurich, Research Priority Programme in Ethics & Swiss  
Re (Meeting the author: Norman Daniels, Co-PI with N. Biller-  
Andorno; CHF 9'500)

**SCHOLARSHIPS & FELLOWSHIPS**

2016 German Research Foundation, Mercator Fellowship at Hannover  
Medical School (£29'179 – partially accepted)

2015 University of Oxford, ETHOX Centre, Caroline Miles Visiting  
Scholarship (£2'000 – partially accepted)

2012 Fondation Brocher, Visiting Scholarship (2 months in residence plus  
travel)

2007 – 2010 National Institutes of Health, Intramural Research Training Award  
fellowship (\$87'000 – partially accepted)

2009 & 2010	Swiss National Science Foundation, CH Link award (CHF 4'000)
2004	Carlo-Schmid Program for Internships in International Organizations and EU-Institutions, internship stipend (~€7'000)
2002 – 2003	German Academic Exchange Service, travel stipend (~€7'500)
1999 – 2001	German Academic Exchange Service & German National Merit Foundation, travel stipend (~DM 15'000)
1996 – 2003	German National Merit Foundation, scholarship (~DM 10'000)

## **HONORS & AWARDS**

2022	NIH Director's Award for outstanding efforts to develop and implement the ACTIV-2 trial (Outpatient Monoclonal Antibodies and Other Therapies) under the NIAID Accelerating COVID-19 Therapeutic Interventions and Vaccines Initiative (group award)
2022	NIH Clinical Center (CC) CEO Award for providing COVID-related bioethics consultations contributing to ethical decisions for CC patients, and for CC, NIH, and NIH-lead clinical research around the world (group award)
2016	The Hastings Center, Fellowship
2016 & 2017	King's College London, Teaching Excellence Award (nominee)
2012	International Association of Bioethics and University of California, Pacific Center for Health Policy and Ethics, Mark S. Ehrenreich Prize in Healthcare Ethics Research (second prize; \$500)
1999	University of Freiburg, Student Delegate to the 55 <sup>th</sup> Lindau Nobel Prize Laureates Meeting

## **WORKING GROUPS, COMMITTEES & POLICY CONSULTATION**

2024 – ...	Promoting Equity for Pregnant Adolescents in Research (PREPARE) project, member of the working group (PI: Anne Drapkin Lyerly)
2022 – 2023	AIDS Clinical Trials Group (ACTG), member of the Partner Protection Working Group for HIV cure-related trials involving analytical treatment interruptions
2021 – 2023	HIV Prevention Trials Network (HPTN), member of the Ethics Working Group

2020 – ...	Kompetenznetz Public Health zu COVID-19 (consortium of >15 German-speaking professional societies focusing on public health and COVID-19), member of the ethics working group
2019 – 2023	Promoting Global Clinical Research in Children project, member of the working group (PIs: Enrica Alteri, Barbara Bierer, Steven Joffe, Robert Nelson)
2017 – ...	U.K. Health Research Authority, member of the National Research & Ethics Advisors' Panel
2018 – 2020	Pregnancy & HIV/AIDS: Seeking Equitable Study (PHASES) project, member of the working group (PI: Anne Drapkin Lysterly)
2016 – 2018	Royal College of Physicians, member of the Committee on Ethical Issues in Medicine
2012 – 2016	Council for International Organizations of Medical Sciences, member of the working group to update the 2002 CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects
2013	World Health Organization, member of a working group on the ethics of placebo-controlled vaccine trials
2012	World Medical Association, consultant during the updating process of the 2008 Declaration of Helsinki
2011 – 2012	European Society of Medical Oncology, member of the Ethics Committee
2011	Swiss Ministry of Health, consultant during the drafting process of the Swiss regulations for biomedical research
2005 – 2007	World Health Organization, external advisor during the updating process of the 1991 WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation

#### **CLINICAL & RESEARCH ETHICS CONSULTATION OR REVIEW**

2022 – ....	Attending Bioethics Consultant, Fogarty International Center, National Institutes of Health
2018 – ....	Attending Consultant, Bioethics Consultation Service & Ethics Committee Member, The Clinical Center, National Institutes of Health
2018 – 2022	Attending Bioethics Consultant, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health

- 2011 – 2012 Clinical Ethicist (part-time) and Ethics Committee Member, University Hospital Zurich
- 2007 – 2010 Fellow, Bioethics Consultation Service & Ethics Committee Member, The Clinical Center, National Institutes of Health
- 2007 – 2009 Participant Observer, Institutional Review Board, National Institute of Allergy and Infectious Diseases, National Institutes of Health

### **BOARD ACTIVITIES**

- 2022 – ... GUIDEME – Guidelines for Research Ethics Review in Germany, Scientific Advisory Board member (PI: D. Strech, funded by the German Federal Ministry of Education and Research)
- 2019 – 2021 Heart Failure Clinical Research Network, Data and Safety Monitoring Board member
- 2016 – 2018 European HIV Vaccine Alliance, Scientific Advisory Board member
- 2015 – 2018 Ebola+ programme (Innovative Medicines Initiative), Ethics Board member
- 2015 – 2018 Structure and Transparency in Translational Research project, Scientific Advisory Board member (PI: D. Strech, funded by the German Research Foundation)
- 2014 – 2017 Ethical, Social and Regulatory Aspects of Citizen Science in Biomedicine and Healthcare project, Scientific Advisory Board member (PI: A. Buyx & B. Prainsack, funded by the German Federal Ministry of Education and Research)

### **REFERENCING SERVICE & EDITORIAL ACTIVITIES**

- 2023 – ... Indo-US Clinical Research Ethics Fellowship, Selection Committee member
- 2020 – ... *Theoretical Medicine and Bioethics*, Editorial Advisory Committee member
- 2018 – ... *Hastings Center Report*, Editorial Committee member
- 2018 – ... *Journal of Medical Ethics*, Editorial Board member
- 2017 – ... *Global Bioethics*, Editorial Board member
- 2016 – 2020 *Research Ethics*, International Advisory Board member
- 2015 – 2020 *Journal of Medicine and Philosophy*, Advisory Editorial Board member

- 2014 – ... *Monash Bioethics Review*, Editorial Board member
- 2012 – ... *Research Ethics Forum* book series (Springer), Editorial Board member
- 2005 – ... *Bioethics; Journal of Medical Ethics; Journal of Medicine and Philosophy; Kennedy Institute of Ethics Journal; Medicine, Healthcare and Philosophy; Public Health Ethics; Theoretical Medicine and Bioethics; Monash Bioethics Review; Philosophy, Ethics and Humanities in Medicine; Bioethica Forum; IRB: Ethics & Human Research; Journal of Empirical Research on Human Research Ethics; Research Ethics; Accountability in Research; Ethik in der Medizin; Ethics & International Affairs; Journal of Political Philosophy; Social Science & Medicine; BioSocieties; Science; Lancet; BMJ; PLOS Medicine; Lancet Infectious Diseases; American Journal of Public Health; Journal of General Internal Medicine; Critical Care Medicine; BMJ Open; WHO Bulletin; Pediatrics; Acta Paediatrica; BMC Reproductive Health; Alzheimer's & Dementia; American Journal of Transplantation; Cell & Tissue Banking; Clinical Trials; Health Policy*, reviewer of manuscripts and books
- 2019-20 International Association of Bioethics, member of the International Advisory Committee of 15<sup>th</sup> World Congress on Bioethics
- 2017 The Hastings Center, Fellowship Selection Committee member
- 2016 Wellcome Trust, grant reviewer

## ORGANIZED WORKSHOPS, MEETINGS & SYMPOSIA

- 2023 *Ethics of research priority setting*. Global Forum on Bioethics in Research meeting, Montreux (Planning Committee member)
- 2020 *Third party risk in research: Moving forward on terminology, justifications, and participant protections*. Symposium at the 15<sup>th</sup> World Congress of Bioethics, Philadelphia (with S.K. Shah)
- 2017 *Ethics of novel clinical trial designs*. Global Forum on Bioethics in Research meeting, Bangkok (Planning Committee member)
- 2017 *Ethical design of vaccine trials in emerging infections*. Satellite workshop of the Oxford Global Health and Bioethics International Conference (with N. Eyal, R. Kahn, M. Lipsitch); outcome: paper in *PLoS Medicine* 2018
- 2016 *What is enough? Sufficiency, justice, and health*. Symposium at the 13<sup>th</sup> World Congress of Bioethics, Edinburgh (with C. Fourie)
- 2016 *The ethics of research during an epidemic: Lessons from Ebola*. International workshop at King's College London

- 2015 *Risk-adapted approaches to regulating research: Ethical challenges.* International workshop at King’s College London
- 2014 *The Social Value of Research: Conflicts between science, society, and individuals.* Symposium at the 12<sup>th</sup> World Congress of Bioethics, Mexico City (with S.K. Shah); outcome: *Bioethics* special issue 2017
- 2014 *Evidence-based research regulation?* Symposium at the 12<sup>th</sup> World Congress of Bioethics, Mexico City
- 2012 *How much is enough? Sufficiency and thresholds in health care,* International Workshop at the Ethics Centre, University of Zurich (with C. Fourie and A. Leist); outcome: edited volume with Oxford University Press 2017
- 2012 *What is the Proper Relationship Between Risk and Consent in Biomedical Research?* Symposium at the 11<sup>th</sup> World Congress of Bioethics, Rotterdam (with D. Bromwich)
- 2012 *Who should be listed for transplantation? Psychiatric, legal and ethical aspects,* Symposium at the University Hospital Zurich (with T. Kronen)
- 2009 *Systematic Analysis of Research Risk,* International Workshop at the Department of Bioethics, National Institutes of Health (with E. Emanuel and D. Wendler); outcome: paper in *JAMA* 2010
- 2007 *Meeting the author – Norman Daniels,* International Workshop at the Ethics Centre, University of Zurich; outcome: symposium in the *Journal of Medical Ethics* 2009 (including response by N. Daniels)
- 2006 *Human Cell and Tissue Transplantation – An International Symposium on Ethical and Policy Issues,* Joint International Meeting of the World Health Organization and the University of Zurich (with N. Biller-Andorno, A.M. Capron and L. Noel); outcome: paper in *WHO Bulletin* 2007
- 2006 *Is a universal bioethics possible?* International Workshop at the Ethics Centre, University of Zurich (with N. Biller-Andorno and P. Schaber); outcome: edited volume with *Mentis* 2009

## TEACHING

- 2018 – ... Lecturer on various courses at the National Institutes of Health (“Ethical and Regulatory Aspects of Human Subjects Research”, “Introduction to Bioethics” etc.)
- 2021 – 2023 Convenor, “Introduction to Bioethics” course, Department of Bioethics, The Clinical Center, National Institutes of Health



- 2012 – 2018      Lecturer on a suite of undergraduate and postgraduate programmes: BA / BSc in Global Health & Social Medicine; MA / MSc Bioethics & Society; MSc Global Health & Social Justice; MSc Medicine, Health & Public Policy; MSc Medicine, Science & Society; PG Diploma in Research Methods for Social Science, Health & Medicine; Global Health Summer School
- Supervisor of ~3 BA/BSc and ~3 MSc dissertations per year; Department of Global Health & Social Medicine, King's College London
- 2010 – 2012      Lecturer, PhD programme Biomedical Ethics & Law, Institute of Biomedical Ethics, University of Zurich
- 2005 – 2012  
(on leave 2007-2010)      Lecturer in biomedical ethics for undergraduate and graduate students in medicine, nursing, and law, Institute of Biomedical Ethics, University of Zurich
- 2005 – 2012      Lecturer for physicians, nurses, hospital administrators, etc. in continuing education (Advanced Studies in Applied Ethics, Ethics Centre, University of Zurich; Continuing Education, University Hospital Zurich; Bethesdaspital Basel)
- 2012      Development of the continuing education program for staff at the University Hospital Zurich (with T. Krones)
- 2011 – 2012      Co-author of E-learning courses on research ethics and clinical ethics for undergraduate and graduate students in medicine, Institute of Biomedical Ethics, University of Zurich
- 2003 – 2004      Clinical Instructor, Department of Neonatology, Charité Berlin
- 1998 – 2000      Graduate Teaching Assistant, Institute of Physiology, University of Freiburg

**PHD STUDENTS** (King's College London unless otherwise noted, \*2<sup>nd</sup> or 3<sup>rd</sup> supervisor)

- 2016 – ...      Victoria Charlton: The influence of social values on NICE technology appraisal: an empirical ethics study
- 2016 – 2018      \*Caroline Green: Human rights in care homes: What are the foundations of a 'human rights approach to care' and how could it contribute to enhancing the experience of visiting, living and working in care homes? (PhD awarded in 2019)
- 2015 – 2018      \*Clémence Pinel: The construction of the environment in epigenetics research: a social science study (PhD awarded in 2019)
- 2008 – 2010      Vincent Wettstein: Behavioural dispositions to and attitudes about kidney sales in a regulated kidney market: an exploratory study (Dr med (~MD/PhD) awarded in 2011; University of Zurich)

## **ADMINISTRATIVE RESPONSIBILITIES**

2018 – ...	Member, Senior Faculty Team, Department of Bioethics, The Clinical Center, National Institutes of Health
2021 – 2023	Chair, Post-doctoral Fellowship Selection, Department of Bioethics, The Clinical Center, National Institutes of Health
2016 – 2018	Director of Teaching, Department of Global Health & Social Medicine, King's College London
2015 – 2018	Member, Senior Management Team, Department of Global Health & Social Medicine, King's College London
2015 – 2018	Deputy Director, MA/MSc Bioethics & Society, Department of Global Health & Social Medicine, King's College London
2013 – 2018	Founder and Co-Convenor, London Bioethics Colloquium (with J. Wilson)
2013 – 2018	Founder and Convenor, Medical London Excursions for students in the Department of Global Health & Social Medicine, King's College London
2015 – 2017	Director of Postgraduate Taught (PGT) Studies and Chair of the PGT Education Committee, Department of Global Health & Social Medicine, King's College London
2012 – 2015	Inaugural Co-Director, MA/MSc Bioethics & Society Department of Global Health & Social Medicine, King's College London
2012 – 2015	Steering Committee member, MSc Global Health & Social Justice Department of Global Health & Social Medicine, King's College London
2012 – 2015	Chair, previously Deputy Chair, "Biomedicine, Ethics and Social Justice" Research Group Department of Global Health & Social Medicine, King's College London
2010 – 2012	Recruitment of administrative staff, Institute of Biomedical Ethics, University of Zurich
2005 – 2012 (on leave 2007-2010)	Convenor, bioethics research seminars, Institute of Biomedical Ethics, University of Zurich
2005 – 2012 (on leave 2007-2010)	Academic lead for the library, Institute of Biomedical Ethics, University of Zurich
2005 – 2007	Board member, Center for Ethics, University of Zurich

**LANGUAGES**

German (native speaker), English (fluent), French (proficient)